Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00727532|
Recruitment Status : Terminated (Low Accrual)
First Posted : August 4, 2008
Last Update Posted : July 18, 2013
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving sorafenib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
PURPOSE: This clinical trial is studying how well sorafenib works in treating patients with locally advanced or metastatic kidney cancer.
|Condition or disease||Intervention/treatment||Phase|
|Hereditary Clear Cell Renal Cell Carcinoma Kidney Cancer||Drug: sorafenib tosylate Procedure: diffusion-weighted magnetic resonance imaging||Not Applicable|
- To demonstrate the feasibility and safety of sorafenib tosylate when given prior to nephrectomy or metastasectomy.
- To evaluate the ability of diffusion-weighted magnetic resonance imaging (DW-MRI) to detect early and ongoing microstructural changes in primary and metastatic renal cell carcinoma lesions during neoadjuvant therapy with sorafenib tosylate.
- To correlate early and ongoing microstructural changes in primary and metastatic renal cell carcinoma lesions with pathologic and clinical findings at the time of nephrectomy or metastasectomy.
- To evaluate the ability of changes in DW-MRI to predict subsequent favorable response to treatment (complete or partial response or stable disease) after 4 weeks of therapy.
OUTLINE: Patients receive oral sorafenib tosylate twice daily on days 1-28. Patients then undergo a nephrectomy or metastasectomy in week 5. Patients with residual metastatic disease may continue sorafenib tosylate twice daily and undergo a diffusion-weighted MRI (DW-MRI) every 8 weeks in the absence of disease progression or unacceptable toxicity.
Patients undergo a DW-MRI of the abdomen and pelvis at baseline and prior to week 5 to evaluate microstructure tumor changes and to allow for prediction of sorafenib tosylate benefit. DW-MRI results are correlated with surgical and pathologic findings obtained at week 5.
Resected tumor tissue are analyzed for vascular density and to distinguish apoptotic cell death from necrotic cell death via immunohistochemistry and to measure apoptotic cell death via TUNEL assay.
After completion of study treatment, patients are followed every 3 months for 2 years.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||9 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Correlation of Pathologic Findings After Neo-adjuvant Sorafenib With Results of Diffusion-Weighted Magnetic Resonance Imaging in Patients With Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma|
|Study Start Date :||July 2008|
|Actual Primary Completion Date :||October 2011|
|Estimated Study Completion Date :||June 2015|
Sorafinib 400mg orally twice daily on days 1-28
Drug: sorafenib tosylate
400mg by mouth twice daily for 28 consecutive daysProcedure: diffusion-weighted magnetic resonance imaging
At baseline and just prior to surgery after sorafenib treatment
- MRI apparent diffusion coefficients (ADC) at baseline and week 5 [ Time Frame: Baseline and week 5 ]Patients will undergo a DW-MRI of the pelvis at baseline and prior to week 5 to evaluate microstructure tumor changes and to allow for prediction of sorafenib tosylate benefit
- Tumor response during the neoadjuvant period [ Time Frame: Just prior to study week 5 ]
- Tumor necrotic fraction and pathology [ Time Frame: At time of surgery ]
- Time to progression [ Time Frame: At time of disease progression ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00727532
|United States, Illinois|
|Robert H. Lurie Comprehensive Cancer Center at Northwestern University|
|Chicago, Illinois, United States, 60611-3013|
|Principal Investigator:||Timothy M. Kuzel, MD||Robert H. Lurie Cancer Center|
|Principal Investigator:||Gary R. Mac Vicar, MD||Robert H. Lurie Cancer Center|